Roche receives CE mark for Contivue, its Port Delivery Platform containing Susvimo, for neovascular age-related macular degeneration (nAMD)
(RO) Basel, 04 September 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received the EU CE mark for its Port Delivery Platform containing Susvimo, which will now be known as Contivue® in the EU.6 The device comprises the eye implant through which Susvimo is delivered, and four ancillary devices to initially fill, insert, refill, and remove the implant (if required).6 Susvimo® (ranibizumab injection) 100 mg/mL is currently under review with the European Medicines Agency (EMA) for the treatment of nAMD.6 With immediate and predictable durability, Contivue with Susvimo provides continuous delivery of a customised formulation of ranibizumab directly to the eye.6
Related Questions
How will the CE marking of Contivue with Susvimo affect Roche's upcoming quarterly earnings and revenue forecasts?
What competitive advantages does Contivue offer over existing nAMD delivery platforms from companies like Novartis and Alcon, and how might this influence market share?
When is the EMA decision expected for Susvimo, and what are the potential pricing and reimbursement implications in the EU market?